Contineum Therapeutics Shares Surge 27% After Bristol Myers Squibb Reports Positive Phase 3 Trial Results

Contineum Therapeutics (NASDAQ:CTNM) shares climbed 27% in premarket trading on Monday after Bristol Myers Squibb (NYSE:BMY) reported positive Phase 3 clinical trial results for a pulmonary fibrosis treatment targeting the same biological pathway as Contineum’s lead drug candidate.

Contineum shares were indicated at $16.99 before the market opened, compared with Friday’s closing price of $13.38, as investors reacted to the potential implications of the trial results for the company’s drug development programme.

Bristol Myers Squibb announced that its Phase 3 ALOFT-IPF study of admilparant in adults with idiopathic pulmonary fibrosis (IPF) had met its primary endpoint.

The trial demonstrated a statistically significant improvement in lung function at the 60 mg twice-daily dose compared with placebo, measured by the absolute change in forced vital capacity after 52 weeks.

The findings provide late-stage clinical evidence supporting inhibition of the lysophosphatidic acid receptor 1 (LPA1), a biological pathway involved in the development of fibrosis.

Contineum’s lead drug candidate, PIPE-791, is also an LPA1 antagonist and is currently undergoing Phase 2 clinical evaluation.

The shared mechanism of action has made the outcome of Bristol Myers Squibb’s study particularly relevant to Contineum, as both companies are investigating treatments intended to address the progression of idiopathic pulmonary fibrosis.

IPF is a chronic lung disease characterised by progressive scarring of lung tissue, which reduces respiratory function and can lead to worsening breathing difficulties over time.

LPA1 antagonists are being investigated for their potential to interfere with biological processes involved in tissue scarring, with the aim of slowing disease progression.

Bristol Myers Squibb’s successful Phase 3 study represents an important clinical development for the treatment approach, providing large-scale evidence that targeting LPA1 can produce measurable benefits in patients with IPF.

However, the results do not establish the effectiveness of Contineum’s PIPE-791, which remains at an earlier stage of clinical development and must demonstrate its own efficacy and safety profile.

Investment bank Stifel had previously identified the outcome of the ALOFT-IPF trial as a significant factor in assessing Contineum’s valuation, given the potential implications for the broader LPA1 inhibitor drug class.

The positive results may reduce some uncertainty surrounding the biological target, although differences between the two drug candidates, including their clinical performance and safety characteristics, remain important considerations.

Contineum’s future development prospects will depend on the results of its ongoing Phase 2 programme and any subsequent clinical studies required to support regulatory approval.

The sharp increase in the company’s share price reflects investor interest in the potential read-through from Bristol Myers Squibb’s late-stage clinical success, rather than new clinical results from Contineum itself.

Contineum Therapeutics stock price